NCT06094907View on ClinicalTrials.gov

Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

January 15, 2024

Study Completion Date

March 30, 2024

Conditions
Depressive DisorderDepression, Unipolar
Interventions
DRUG

N,N-Dimethyltryptamine

DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.

Trial Locations (1)

59012300

Hospital Universitário Onofre Lopes, Natal

All Listed Sponsors
lead

Universidade Federal do Rio Grande do Norte

OTHER

NCT06094907 - Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression | Biotech Hunter | Biotech Hunter